259 related articles for article (PubMed ID: 16938752)
1. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis.
Frederiksen B; Pressler T; Hansen A; Koch C; Høiby N
Acta Paediatr; 2006 Sep; 95(9):1070-4. PubMed ID: 16938752
[TBL] [Abstract][Full Text] [Related]
2. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
3. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis].
von der Schulenburg JM; Greiner W; von der Hardt H
Med Klin (Munich); 1995 Apr; 90(4):220-4. PubMed ID: 7776934
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
[TBL] [Abstract][Full Text] [Related]
5. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S
Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
[TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
7. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis.
Paul K; Rietschel E; Ballmann M; Griese M; Worlitzsch D; Shute J; Chen C; Schink T; Döring G; van Koningsbruggen S; Wahn U; Ratjen F;
Am J Respir Crit Care Med; 2004 Mar; 169(6):719-25. PubMed ID: 14684561
[TBL] [Abstract][Full Text] [Related]
8. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha.
Ratjen F; Paul K; van Koningsbruggen S; Breitenstein S; Rietschel E; Nikolaizik W
Pediatr Pulmonol; 2005 Jan; 39(1):1-4. PubMed ID: 15532079
[TBL] [Abstract][Full Text] [Related]
9. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the Epidemiologic Registry of Cystic Fibrosis.
Hodson ME; McKenzie S; Harms HK; Koch C; Mastella G; Navarro J; Strandvik B;
Pediatr Pulmonol; 2003 Nov; 36(5):427-32. PubMed ID: 14520726
[TBL] [Abstract][Full Text] [Related]
10. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
Pirzada OM; McGaw J; Taylor CJ; Everard ML
J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
[TBL] [Abstract][Full Text] [Related]
11. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
[TBL] [Abstract][Full Text] [Related]
12. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function.
Ren CL; Morgan WJ; Konstan MW; Schechter MS; Wagener JS; Fisher KA; Regelmann WE;
Pediatr Pulmonol; 2007 Jun; 42(6):513-8. PubMed ID: 17469151
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
Saiman L; Mayer-Hamblett N; Campbell P; Marshall BC;
Am J Respir Crit Care Med; 2005 Oct; 172(8):1008-12. PubMed ID: 16040785
[TBL] [Abstract][Full Text] [Related]
15. DNase in stable cystic fibrosis infants: a pilot study.
Berge MT; Wiel Ev; Tiddens HA; Merkus PJ; Hop WC; de Jongste JC
J Cyst Fibros; 2003 Dec; 2(4):183-8. PubMed ID: 15463871
[TBL] [Abstract][Full Text] [Related]
16. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
Suri R; Metcalfe C; Wallis C; Bush A
Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
[TBL] [Abstract][Full Text] [Related]
17. Treatment of lobar atelectasis with bronchoscopically administered recombinant human deoxyribonuclease in cystic fibrosis?
McLaughlin AM; McGrath E; Barry R; Egan JJ; Gallagher CG
Clin Respir J; 2008 Apr; 2(2):123-6. PubMed ID: 20298317
[TBL] [Abstract][Full Text] [Related]
18. No positive effect of rhdnase on the pulmonary colonization in children with cystic fibrosis.
Bonestroo HJ; Slieker MG; Arets HG
Monaldi Arch Chest Dis; 2010 Mar; 73(1):12-7. PubMed ID: 20499789
[TBL] [Abstract][Full Text] [Related]
19. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
20. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
